PARP7 Suppresses Radiation-induced Necroptosis and Abscopal Immunity

  • Res Sq. 2025 Nov 7:rs.3.rs-7881707. doi: 10.21203/rs.3.rs-7881707/v1.
Gaorav Gupta  1 ,  Anna Goddard  1 ,  Sierra McDonald  1 ,  Lynn Lerner  1 ,  Maxwell Finkelstein  1 ,  Qinhong Wang  1 ,  Faeze Gharibpoor  1 ,  Min-Guk Cho  1 ,  Simon Ellington  1 ,  Matthew Sutcliffe  1 ,  Kevin Raynard Mott  2 ,  William Green  1 ,  Amber Gomez  1 ,  Steven Vensko  1 ,  J Justin Milner  3 ,  Benjamin Vincent  4 ,  Charles Perou  1
Affiliations
  • 1. University of North Carolina at Chapel Hill.
  • 2. University of North Carolina School of Medicine.
  • 3. University of North Carolina.
  • 4. UNC-Chapel Hill.
Abstract

The abscopal effect, in which local radiotherapy (RT) drives regression of distant Tumors, remains unpredictable and mechanistically elusive. Using a panel of p53-null murine Breast Cancer Models, we identified tumor-intrinsic determinants of abscopal competence to RT and immune checkpoint inhibitors (ICI). Abscopal-competent Tumors exhibited heightened type I interferon stimulated gene (ISG) expression, induction of the Necroptosis mediator ZBP1, and recruitment of antigen-presenting cells (APCs) and effector T cells in distant Tumors. Transcriptomic analyses revealed PARP7 as a tumor-intrinsic suppressor of RT-induced ISGs and Necroptosis. Pharmacologic PARP7 inhibition amplified RT-driven ISGs and ZBP1-dependent Necroptosis. In vivo, PARP7 blockade combined with RT + ICI conferred abscopal competency to resistant Tumors, improving distant tumor control, systemic immune activation, and survival. Notably, ZBP1 loss abrogated these effects, preventing APC recruitment and T cell priming. These findings establish PARP7 and Necroptosis as opposing regulators of abscopal responses and nominate PARP7 inhibition as a strategy to overcome RT + ICI resistance.

Products